STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Merkel Cell Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    Patient must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (American Joint Committee on Cancer [AJCC] version 8) I-IIIb. Stage I patients with negative sentinel lymph node biopsy are ineligible. Patients who have a positive biopsy or for whom no biopsy was done are eligible.

You may not be eligible for this study if the following are true:

  • 1. Patients with distant metastatic disease (stage IV). 2. Patients with a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. 3. Patient with a history of distant metastatic disease.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.